• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Discordance with Activity: Humanized Exposures of Ceftazidime-Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae in a Murine Lung Infection Model.与活性的不一致：在小鼠肺部感染模型中，头孢他啶-阿维巴坦、氨曲南和替加环素单独及联合使用对产新德里金属β-内酰胺酶的肺炎克雷伯菌的人源化暴露情况。
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00486-17. Print 2017 Jul.
2
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
3
Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies.肺炎克雷伯菌对依拉环素耐药的产生及协同治疗策略的伴随敏感性指导设计。
Microbiol Spectr. 2022 Oct 26;10(5):e0139022. doi: 10.1128/spectrum.01390-22. Epub 2022 Aug 16.
4
Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland.波兰一家单中心对 23 例产新德里金属β-内酰胺酶（NDM）肺炎克雷伯菌感染患者使用头孢他啶/阿维巴坦和氨曲南治疗的结果。
Eur J Clin Microbiol Infect Dis. 2024 Aug;43(8):1579-1587. doi: 10.1007/s10096-024-04859-y. Epub 2024 May 29.
5
Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.针对产 NDM-和 CTX-M 型肺炎克雷伯菌的细胞壁合成和外膜完整性的靶向治疗机制研究。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0052722. doi: 10.1128/aac.00527-22. Epub 2022 Aug 4.
6
Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.监测头孢他啶-阿维巴坦和氨曲南在治疗一株携带肺炎克雷伯菌碳青霉烯酶 4 型和新德里金属β-内酰胺酶 1 型的多药耐药肠杆菌引起的血流感染中的浓度。
Clin Infect Dis. 2020 Aug 14;71(4):1095-1098. doi: 10.1093/cid/ciz1155.
7
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?头孢他啶-阿维巴坦和氨曲南能否克服肠杆菌科细菌中金属β-内酰胺酶介导的β-内酰胺耐药性？
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02243-16. Print 2017 Apr.
8
Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae.单独使用头孢他啶/阿维巴坦或与氨曲南联合使用治疗对黏菌素耐药且产碳青霉烯酶的肺炎克雷伯菌。
J Antimicrob Chemother. 2018 Feb 1;73(2):542-544. doi: 10.1093/jac/dkx393.
9
Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-lactamase-producing Enterobacteriaceae in a murine thigh infection model.在小鼠大腿感染模型中，头孢他啶单独及与阿维巴坦联合使用对产新德里金属β-内酰胺酶肠杆菌科细菌的体内意外活性。
Antimicrob Agents Chemother. 2014 Nov;58(11):7007-9. doi: 10.1128/AAC.02662-14. Epub 2014 Sep 15.
10
The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.头孢他啶、头孢洛林和氨曲南与阿维巴坦联合应用对目标革兰氏阴性菌的抗生素后效应及β-内酰胺酶抑制剂后效应
Lett Appl Microbiol. 2016 Aug;63(2):96-102. doi: 10.1111/lam.12592.

引用本文的文献

1
A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.头孢他啶/阿维巴坦联合其他抗菌药物对耐碳青霉烯革兰氏阴性菌体外抗菌活性的系统评价及单菌属水平的Meta分析
J Antimicrob Chemother. 2025 Feb 3;80(2):334-346. doi: 10.1093/jac/dkae451.
2
, and clinical studies comparing the efficacy of ceftazidime-avibactam monotherapy with ceftazidime-avibactam-containing combination regimens against carbapenem-resistant and multidrug-resistant isolates or infections: a scoping review.比较头孢他啶-阿维巴坦单药治疗与含头孢他啶-阿维巴坦联合治疗方案对碳青霉烯耐药和多重耐药分离株或感染的疗效的临床研究：一项范围综述
Front Med (Lausanne). 2023 Sep 4;10:1249030. doi: 10.3389/fmed.2023.1249030. eCollection 2023.
3
The place of new antibiotics for Gram-negative bacterial infections in intensive care: report of a consensus conference.重症监护中新型抗生素用于革兰氏阴性菌感染的地位：共识会议报告
Ann Intensive Care. 2023 Jul 4;13(1):59. doi: 10.1186/s13613-023-01155-4.
4
Evaluation of Aztreonam and Ceftazidime/Avibactam Synergism against by MALDI-TOF MS.通过基质辅助激光解吸电离飞行时间质谱法评估氨曲南和头孢他啶/阿维巴坦对……的协同作用
Antibiotics (Basel). 2023 Jun 16;12(6):1063. doi: 10.3390/antibiotics12061063.
5
Antimicrobial resistance in Gram-negative bacilli in Spain: an experts' view.西班牙革兰氏阴性杆菌的抗菌药物耐药性：专家观点。
Rev Esp Quimioter. 2023 Feb;36(1):65-81. doi: 10.37201/req/119.2022. Epub 2022 Dec 13.
6
Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults.健康成年人中头孢他啶-阿维巴坦（COMBINE）联合氨曲南的药代动力学：一项 1 期、开放标签研究。
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0093622. doi: 10.1128/aac.00936-22. Epub 2022 Nov 17.
7
Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers.一项在健康成年志愿者中开展的 I 期、开放性标签研究评估头孢他啶-阿维巴坦与氨曲南联用的安全性（COMBINE）。
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0093522. doi: 10.1128/aac.00935-22. Epub 2022 Nov 17.
8
Treatment of Severe Infections Due to Metallo-Betalactamases in Critically Ill Patients.危重症患者中金属β-内酰胺酶所致严重感染的治疗
Antibiotics (Basel). 2022 Jan 24;11(2):144. doi: 10.3390/antibiotics11020144.
9
Activity of β-Lactam Antibiotics against Metallo-β-Lactamase-Producing in Animal Infection Models: a Current State of Affairs.β-内酰胺类抗生素对动物感染模型中产金属β-内酰胺酶的活性：现状。
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.02271-20.
10
Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales.产金属β-内酰胺酶肠杆菌科细菌的治疗选择
Infect Drug Resist. 2021 Jan 18;14:125-142. doi: 10.2147/IDR.S246174. eCollection 2021.

本文引用的文献

1
Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug-Resistant Klebsiella pneumoniae in a Multivisceral Transplant Patient.通过对一名多脏器移植患者广泛耐药肺炎克雷伯菌进行分子特征分析来应用“精准医学”
Clin Infect Dis. 2017 Aug 15;65(4):701-702. doi: 10.1093/cid/cix387.
2
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?头孢他啶-阿维巴坦和氨曲南能否克服肠杆菌科细菌中金属β-内酰胺酶介导的β-内酰胺耐药性？
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02243-16. Print 2017 Apr.
3
Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-lactamase-producing Enterobacteriaceae in a murine thigh infection model.在小鼠大腿感染模型中，头孢他啶单独及与阿维巴坦联合使用对产新德里金属β-内酰胺酶肠杆菌科细菌的体内意外活性。
Antimicrob Agents Chemother. 2014 Nov;58(11):7007-9. doi: 10.1128/AAC.02662-14. Epub 2014 Sep 15.
4
Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.人体模拟研究表明，氨曲南和氨曲南-阿维巴坦对包括产金属β-内酰胺酶在内的具有挑战性的革兰氏阴性菌具有活性。
Antimicrob Agents Chemother. 2013 Jul;57(7):3299-306. doi: 10.1128/AAC.01989-12. Epub 2013 May 6.
5
Tigecycline displays in vivo bactericidal activity against extended-spectrum-β-lactamase-producing Enterobacteriaceae after 72-hour exposure period.替加环素在 72 小时暴露期后对产超广谱β-内酰胺酶的肠杆菌科具有体内杀菌活性。
Antimicrob Agents Chemother. 2013 Jan;57(1):640-2. doi: 10.1128/AAC.01824-12. Epub 2012 Oct 31.
6
Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.头孢他啶和头孢他啶-阿维巴坦人体模拟剂量对铜绿假单胞菌的体外和体内疗效比较。
Antimicrob Agents Chemother. 2012 Dec;56(12):6137-46. doi: 10.1128/AAC.00851-12. Epub 2012 Sep 17.
7
Global spread of Carbapenemase-producing Enterobacteriaceae.产碳青霉烯酶肠杆菌科的全球传播。
Emerg Infect Dis. 2011 Oct;17(10):1791-8. doi: 10.3201/eid1710.110655.
8
Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.NXL104 联合β-内酰胺类药物对产 A 类和 C 类β-内酰胺酶的基因特征明确的大肠埃希菌和肺炎克雷伯菌的活性。
Antimicrob Agents Chemother. 2011 May;55(5):2434-7. doi: 10.1128/AAC.01722-10. Epub 2011 Feb 28.
9
Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae.NXL104 联合头孢他啶和氨曲南对产碳青霉烯酶肠杆菌科的活性。
Antimicrob Agents Chemother. 2011 Jan;55(1):390-4. doi: 10.1128/AAC.00756-10. Epub 2010 Nov 1.
10
Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.替加环素对实验性肺炎模型中耐甲氧西林金黄色葡萄球菌的药效学特征。
Antimicrob Agents Chemother. 2009 Dec;53(12):5060-3. doi: 10.1128/AAC.00985-09. Epub 2009 Sep 8.

与活性的不一致：在小鼠肺部感染模型中，头孢他啶-阿维巴坦、氨曲南和替加环素单独及联合使用对产新德里金属β-内酰胺酶的肺炎克雷伯菌的人源化暴露情况。

Discordance with Activity: Humanized Exposures of Ceftazidime-Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae in a Murine Lung Infection Model.

作者信息

Monogue M L, Abbo L M, Rosa R, Camargo J F, Martinez O, Bonomo R A, Nicolau D P

机构信息

Center for Anti-infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.

Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.

出版信息

Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00486-17. Print 2017 Jul.

DOI:10.1128/AAC.00486-17
PMID:28416558
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5487677/
Abstract

The management of infections with New Delhi metallo-beta-lactamase-1 (NDM)-producing bacteria remains clinically challenging given the multidrug resistant (MDR) phenotype associated with these bacteria. Despite resistance , ceftazidime-avibactam previously demonstrated activity against NDM-positive Herein, we observed synergy with ceftazidime-avibactam and aztreonam against an MDR harboring NDM. , humanized doses of ceftazidime-avibactam monotherapy resulted in >2 log CFU bacterial reduction; therefore, no synergy was observed.

摘要

鉴于产新德里金属β-内酰胺酶-1（NDM）细菌的多重耐药（MDR）表型，对这类细菌感染的管理在临床上仍然具有挑战性。尽管存在耐药性，但头孢他啶-阿维巴坦先前已证明对NDM阳性菌有活性。在此，我们观察到头孢他啶-阿维巴坦与氨曲南对一株携带NDM的MDR菌具有协同作用。然而，人源化剂量的头孢他啶-阿维巴坦单药治疗导致细菌减少>2个对数CFU；因此，未观察到协同作用。